Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,875 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06405139RecruitingPhase 2
Chemo combo (nanoliposomal irinotecan, oxaliplatin, capecitabine) before surgery for locally advanced colorectal cancer
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
BeijingAges 18–70 - NCT06405113RecruitingPhase 2
Fecal transplant, chemo, and immunotherapy for advanced stomach cancer
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
ChangzhouAges 18–80 - NCT06409065Recruiting
Emotional and spiritual support for advanced cancer and caregivers
This study offers a program to help people with advanced cancer and their caregivers cope with emotional and spiritual distress. It involves talking with a counselor together to improve your well-being.
Houston, TexasAges 18 years+ - NCT06409390RecruitingPhase 2
Sequential therapy based on tumor evolution for breast cancer
This trial tests a sequence of different treatments for breast cancer that has spread, based on how the cancer evolves. The goal is to find a personalized treatment plan that may work better over time.
Tampa, FloridaAges 18 years+ - NCT06413680RecruitingPhase 1/Phase 2
Study of REGN10597 with or without cemiplimab for advanced solid tumors
This study tests a new drug called REGN10597, either alone or with cemiplimab, for people with advanced solid tumors (like melanoma or kidney cancer) that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06413992RecruitingPhase 2
Camrelizumab plus fluzoparib for TP53-mutated endometrial cancer
This trial tests a combination of two drugs, camrelizumab (an immunotherapy) and fluzoparib (a PARP inhibitor), for people with a specific type of endometrial cancer that has a TP53 gene mutation. It may offer a new option for advanced or recurrent disease after limited prior treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06414590RecruitingPhase 2
Tebentafusp before surgery for eye melanoma
This trial tests a drug called Tebentafusp for a type of eye melanoma (uveal melanoma) that is too large to be removed without taking out the whole eye. The goal is to see if the drug can shrink the tumor before deciding on surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06417008RecruitingPhase 2/Phase 3
Combination targeted therapy for advanced EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (HS-20117 and aumolertinib) in people with advanced EGFR-mutant lung cancer who haven't had treatment yet. The goal is to see if the combination works better than current standard treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06420206Recruiting
Goals of care discussion in the ER for advanced cancer
This study is for people with advanced lung or GI cancer who come to the emergency room at MD Anderson. It’s testing a conversation to help you and your doctor discuss your goals and wishes for care.
Houston, TexasAges 18 years+ - NCT06425926RecruitingPhase 1/Phase 2
Study of GIM-531 in advanced solid tumors
This study tests a new oral drug, GIM-531, alone and in combination with an anti-PD-1 therapy for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06427460RecruitingPhase 2
Focused radiation therapy for solid tumors
This trial tests a special type of radiation that delivers a higher dose to the center of the tumor while limiting radiation to nearby healthy organs. It's for people with certain solid tumors that haven't spread widely or have only a few metastases.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06429813Recruiting
Remote exercise program for men with metastatic prostate cancer
This trial tests whether a remotely supervised exercise program (walking and stationary cycling) can help men with metastatic prostate cancer who are starting hormone therapy. Participation involves following an exercise plan at home and may help manage side effects.
Charlottesville, VirginiaAges 18 years+ - NCT06431594RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called Mocertatug Rezetecan for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called B7-H4 on cancer cells to try to slow or shrink the tumor.
Birmingham, AlabamaAges 18 years+ - NCT06438822RecruitingPhase 2
Immunotherapy plus chemo for advanced bile duct cancer
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
Chengdu, SichuanAges 18–75 - NCT06441773Recruiting
Lung rehab for advanced lung cancer on maintenance therapy
This study tests if a respiratory (breathing) rehabilitation program can improve quality of life for people with advanced non-small cell lung cancer who are on maintenance treatment after initial chemotherapy and immunotherapy.
BrestAges 18 years+ - NCT06446401Recruiting
Triple vs double therapy for widespread prostate cancer
This trial compares two treatment approaches for men whose prostate cancer has spread widely and is still responding to hormone therapy. It tests whether using three drugs together (triple therapy) works better than two drugs (double therapy) to control the cancer longer.
Uppsala, Region UppsalaAges 18 years+ - NCT06449989Recruiting
Comparing genetics of colorectal cancer and its brain spread
This study compares the genetics of the original colorectal cancer with the cancer that has spread to the brain. It aims to understand how the tumor changes when it metastasizes, which may help guide future treatments.
Moscow, MoscowAges 18 years+ - NCT06450548Recruiting
PSMA and FDG PET scans before 177Lu-PSMA therapy
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
RouenAges 18 years+ - NCT06452160RecruitingPhase 1
Study of BGC515 for advanced solid tumors
This trial tests an experimental drug called BGC515 for people with advanced solid tumors, including mesothelioma and EHE, that have not responded to standard treatments. The drug works by targeting a specific cell signaling pathway (Hippo) that may be involved in cancer growth.
Houston, TexasAges 18 years+ - NCT06456515Recruiting
Regorafenib, sintilimab, and electroacupuncture for advanced colorectal cancer
This trial tests a combination of two drugs (regorafenib and sintilimab) plus electroacupuncture for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to see if this triple therapy can help shrink tumors or slow the cancer's growth.
ChangzhouAges 18–75 - NCT06457503RecruitingPhase 4
Toripalimab plus chemo for advanced nasopharyngeal cancer
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people whose nasopharyngeal cancer has come back or spread. It is for those who haven't yet received other treatments for this advanced stage.
Little Rock, ArkansasAges 12 years+ - NCT06459687RecruitingPhase 3
Socazolimab for first-line treatment of advanced cervical cancer
This phase 3 trial tests a new immunotherapy drug called socazolimab combined with chemotherapy as a first treatment for cervical cancer that has come back, spread, or cannot be removed with surgery or radiation. The goal is to see if it helps shrink tumors and improves survival.
Hefei, AnhuiAges 18–75 - NCT06459791Recruiting
Personalized treatment for advanced breast cancer using lab-grown tumor models
This trial tests a personalized approach to cancer treatment. Doctors will grow a ‘mini-tumor’ from a biopsy of your cancer in the lab to help find the best therapy for you. It is for people with advanced breast cancer that has not responded well to standard treatments.
ParisAges 18 years+ - NCT06460298RecruitingPhase 1/Phase 2
ProAgio and gemcitabine for triple-negative breast cancer that has spread
This trial tests a new drug called ProAgio combined with the chemotherapy gemcitabine for people with triple-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Atlanta, GeorgiaAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,875 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.